Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Clinical trial NCT00913913 · TERMINATED
Trial details
- NCT number
- NCT00913913
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-01
- Primary completion
- 2013-01-01
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.